CRA provided testimony on behalf of plaintiff in litigation regarding a health plan’s use of MFN clauses with hospitals. CRA identified several mechanisms by which the MFN clauses were likely to reduce competition in this matter and demonstrated that they had historically harmed competitors. CRA also analyzed whether this harm to competition was offset by the procompetitive effects of MFN clauses.
AI in Health Care: Case Law and Enforcement Trends
Their discussion explores pressing issues surrounding artificial intelligence in healthcare, including antitrust concerns, patient-facing applications, claims...